Drug intelligence / Profile preview

MIC2091

Development stage: Preclinical
Lead developer: Micar Innovation
Modality: Small Molecules

Overview

MIC2091 is a preclinical-stage small molecule therapeutic being developed by Micar Innovation for the treatment of cardiomyopathy. It was identified through Micar Innovation's proprietary drug discovery platform, which focuses on the development of first-in-class small molecules. As of the current pipeline disclosure, the specific biological target and mechanism of action for MIC2091 remain undisclosed. The drug is part of a broader pipeline of wholly-owned small molecule candidates targeting various diseases including cancer, chronic pain, and rare genetic disorders.

Beyond the preview

Go deeper on MIC2091.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIC2091.

Explore the full profile